<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03664960</url>
  </required_header>
  <id_info>
    <org_study_id>AK002-003X</org_study_id>
    <nct_id>NCT03664960</nct_id>
  </id_info>
  <brief_title>An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis</brief_title>
  <official_title>A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Safety and Tolerability of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allakos, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allakos, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, open-label, extension study to assess the safety and tolerability of&#xD;
      AK002, given monthly for up to 26 doses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 14, 2018</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability of AK002 by evaluating adverse events assessed using the CTCAE version 4.03</measure>
    <time_frame>Day 785 (End of Study)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety and tolerability of AK002 as assessed by symptom-directed physical examination of reported or observed patient symptoms warranting examination, including assessments of possible infusion site reactions and infusion-related reactions</measure>
    <time_frame>Day 1 to Day 785 (End of Study)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of symptoms of EG and/or EoD (formerly referred to as EGE) using a daily disease-specific patient questionnaire (PRO Questionnaire)</measure>
    <time_frame>Baseline to Day 785 (End of Study)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the number of eosinophils in gastric and/or duodenal mucosa</measure>
    <time_frame>Baseline to Day 729</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Eosinophilic Gastritis</condition>
  <condition>Eosinophilic Gastroenteritis</condition>
  <condition>Eosinophilic Duodenitis</condition>
  <arm_group>
    <arm_group_label>1 to 3.0 mg/kg of AK002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive 26 monthly doses of AK002: a first dose of 1 mg/kg, followed by monthly doses of 3 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK002</intervention_name>
    <description>AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.</description>
    <arm_group_label>1 to 3.0 mg/kg of AK002</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide written informed consent.&#xD;
&#xD;
          2. Completed Study AK002-003, defined as having received 4 infusions of study drug and&#xD;
             followed through Day 113 (Â±3 days) in Study AK002-003 and willing to begin extended&#xD;
             dosing on or about Day 113.&#xD;
&#xD;
          3. Able and willing to comply with all study procedures.&#xD;
&#xD;
          4. Female patients must be either post-menopausal for at least 1 year or surgically&#xD;
             sterile (tubal ligation, hysterectomy, or bilateral oophorectomy) for at least 3&#xD;
             months, or if of childbearing potential, have a negative pregnancy test and agree to&#xD;
             use dual methods of contraception, or abstain from sexual activity until the end of&#xD;
             the study, or for 120 days following the last dose of study drug, whichever is longer.&#xD;
&#xD;
          5. Male patients with female partners of childbearing potential must agree to use a&#xD;
             highly effective method of contraception until the end of the study or for 120 days&#xD;
             following the last dose of study drug, whichever is longer. All fertile men with&#xD;
             female partners of childbearing potential should be instructed to contact the&#xD;
             Investigator immediately if they suspect their partner might be pregnant at any time&#xD;
             during study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Poor tolerance to previous administration of AK002 in the opinion of the Investigator.&#xD;
&#xD;
          2. Known hypersensitivity to any constituent of the study drug.&#xD;
&#xD;
          3. Any disease, condition (medical or surgical), or cardiac abnormality, which, in the&#xD;
             opinion of the Investigator, would place the patient at increased risk.&#xD;
&#xD;
          4. Planned or expected vaccination with live attenuated vaccines during the treatment, or&#xD;
             vaccination expected within 5 half-lives (4 months) of AK002 administration.&#xD;
&#xD;
          5. Women who are pregnant, breastfeeding, or planning to become pregnant while&#xD;
             participating in the study.&#xD;
&#xD;
          6. Any other reason that, in the opinion of the Investigator or Medical Monitor, makes&#xD;
             the patient unsuitable for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Paterson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Allakos, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenician Centers for Research and Innovation</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventura Clinical Trials</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIH</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinSearch</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avant Research Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2018</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eosinophilic Gastritis</keyword>
  <keyword>Eosinophilic Gastroenteritis</keyword>
  <keyword>Eosinophil</keyword>
  <keyword>EG</keyword>
  <keyword>EGE</keyword>
  <keyword>EGID</keyword>
  <keyword>Eosinophilic gastrointestinal disorders</keyword>
  <keyword>Eosinophilic Duodenitis</keyword>
  <keyword>EoD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
    <mesh_term>Enteritis</mesh_term>
    <mesh_term>Duodenitis</mesh_term>
    <mesh_term>Eosinophilia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

